echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Under the froth of the "Innovative Era", the "involution" of biological products is becoming fierce

    Under the froth of the "Innovative Era", the "involution" of biological products is becoming fierce

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In order to fully grasp the progress of clinical trials in China's new drug registration and strengthen drug regulatory capacity building, CDE based on the registration information of the drug clinical trial registration and information disclosure platform, on November 10, 2021, the CDE official website released the "China New Drug Registration Clinical Trials Annual Report (" 2020)”, this is the first time that CDE has conducted a comprehensive analysis of the current status of clinical trials of new drug registration in China.


    PART 01.


    PART 01.


    (1) GMP Appendix-"Biological Products" on November 03, 2005 (Draft for Solicitation of Comments):

    Biological products are microorganisms (bacteria, viruses, bacteriophages, ricks Secondary bodies, parasites, etc.


    (2) The three general rules of the 2020 edition of the Pharmacopoeia on December 30, 2020:

    Biological Products (Biological Products) refer to preparations that use microorganisms, cells, animal or human-derived tissues and body fluids as starting materials and are made with biological technology for the prevention, treatment and diagnosis of human diseases, such as vaccines, blood products, biotech drugs, probiotics, immunomodulators, diagnostic agents and the like


    PART 02.


    PART 02.


    PART 03.


    PART 03.


    PART 04.


    The "Annual Report on the Current Status of Clinical Trials for New Drug Registration in China (2020)" sorts out and analyzes the outstanding issues in the current status of clinical trials for new drug registration in China.


    (1) The "Annual Report on the Current Status of Clinical Trials of New Drug Registration in China (2020)" shows that there has been an "involution" in the field of bio-innovative drugs.


    (2) The top 10 targets with the largest number of clinical trials are also mainly concentrated in PD-1, etc.


    The PD-1 series of drugs is just a microcosm of the homogenization of R&D by domestic pharmaceutical companies.


    Subsequent CDE will report on new drug registration clinical trials on an annual basis, relying on China's new drug registration clinical trial registration data, focus on regulatory innovation, improve regulatory efficiency, strengthen communication with the industry in the modernization of drug regulatory capabilities, increase information transparency, and promote High-quality and healthy development of clinical trials of new drugs in China


    references

    [1]

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.